Chiesi agrees $191 million diabetes drug deal with Phenomix
This article was originally published in Scrip
Executive Summary
Chiesi has agreed to pay up to $191 million for the rights to Phenomix's type 2 diabetes treatment, dutogliptin (PHX-1149), in Europe and some emerging markets.